Earnings Call Transcript is enclosed.
IKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
IKS Health reported strong Q4 FY26 results with revenue of INR 857 crores (18.5% YoY growth, 13% in constant currency) and EBITDA of INR 300 crores (35% margin). The company grew revenue 20% YoY for the full year to INR 3,193 crores while keeping headcount growth to just 5.3%, demonstrating operating leverage. PAT grew 48% YoY to INR 721 crores, supported by debt reduction from INR 850 crores to INR 251 crores. The company announced two strategic moves: the pending acquisition of TruBridge for the rural healthcare market ($162 billion TAM) and an acqui-hire of ARAI for neuro-symbolic AI capabilities. Key product launches include Scribble Select (multi-variant ambient AI scribing) and MyCare Hub (agentic patient engagement platform). The company has set a True North vision to reach INR 3,000 crore EBITDA by FY30.
Strong operational performance with margin expansion and significant debt reduction positions the company well. The announced acquisitions (TruBridge and ARAI) add growth vectors in rural healthcare and AI capabilities, though pending regulatory approvals add some execution risk.